ERBB2 and gastric cancer: Moreover, these findings validate the assumption of equivalent efficacy of the CT backbone made in this NMA and further strengthen the conclusions about the efficacy of tislelizumab + CT in the 1L treatment of HER2-negative GC/GEJC.